PMID- 37543907
OWN - NLM
STAT- MEDLINE
DCOM- 20230808
LR  - 20240214
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Print)
IS  - 1029-2977 (Linking)
VI  - 25
IP  - 12
DP  - 2022 Dec 1
TI  - Association Between Human Leukocyte Antigens and Graft-Versus-Host Disease 
      Occurrence in Allogeneic Hematopoietic Stem Cell Transplantation - A 10-Year 
      Experience on Iranian Patients.
PG  - 798-806
LID - 10.34172/aim.2022.125 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA) molecules mediate critical roles in 
      determining responsiveness or non-responsiveness of the immune system, especially 
      in transplantation. Some studies have shown a possible association between 
      certain HLA alleles and some allogeneic hematopoietic stem cell transplantation 
      (allo-HSCT) outcomes such as acute/chronic graft-versus-host disease 
      (aGVHD/cGVHD) and overall survival (OS). In the current study, we investigated 
      any possible association of HLA subclasses and acute/chronic GVHD occurrence as 
      well as OS in patients receiving HLA-matched sibling allo-HSCT. METHODS: We 
      retrospectively evaluated the association of various HLA alleles with the 
      incidence of aGVHD, cGVHD, and OS of 162 patients who received allo-HSCT from 
      HLA-matched sibling between 2009-2018 at Taleghani hospital in Tehran. RESULTS: 
      We found that the incidence of aGVHD grades II-IV was higher among patients who 
      had HLA-B*07 (P=0.031) and HLA-DRB1*07 (P=0.052). The presence of HLA-A*01 was 
      associated with 4.5-fold greater odds of incidence in the extensive-type of cGVHD 
      (P=0.009). Furthermore, HLA-A*03 (P=0.089), HLA-B*13(P=0.013), HLA-B*40 
      (P=0.042), HLA-DRB1*02 (P=0.074), and HLA-DRB1*04 (P=0.039) were associated with 
      a lower rate of OS. CONCLUSION: This study suggests that certain HLA alleles 
      might influence the incidence and severity of acute or chronic GVHD in the 
      context of HLA-matched sibling allo-HSCT. In addition, some specific HLA alleles 
      help predict OS in allo-HSCT recipients. These results might be helpful in 
      estimating the incidence of aGVHD, cGVHD, and OS as well as designing 
      personalized therapy.
CI  - (c) 2022 The Author(s). This is an open-access article distributed under the terms 
      of the Creative Commons Attribution License 
      (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
      distribution, and reproduction in any medium, provided the original work is 
      properly cited.
FAU - Hamidpour, Mohsen
AU  - Hamidpour M
AUID- ORCID: 0000-0002-3658-1551
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Roshandel, Elham
AU  - Roshandel E
AUID- ORCID: 0000-0002-3698-4342
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Ghaffari Nazari, Haniyeh
AU  - Ghaffari Nazari H
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Sankanian, Ghazaleh
AU  - Sankanian G
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Bonakchi, Hossein
AU  - Bonakchi H
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Salimi, Maryam
AU  - Salimi M
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Salari, Sina
AU  - Salari S
AUID- ORCID: 0000-0001-8298-2578
AD  - Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20221201
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - Iran/epidemiology
MH  - Retrospective Studies
MH  - HLA-DRB1 Chains
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Graft vs Host Disease/genetics
MH  - HLA Antigens/genetics
PMC - PMC10685839
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Graft-versus-host disease
OT  - Human leukocyte antigen
OT  - Survival
COIS- Competing Interests All authors declare that they have no conflict of interest.
EDAT- 2023/08/06 19:15
MHDA- 2023/08/08 06:42
PMCR- 2022/12/01
CRDT- 2023/08/06 12:21
PHST- 2020/08/25 00:00 [received]
PHST- 2021/11/20 00:00 [accepted]
PHST- 2023/08/08 06:42 [medline]
PHST- 2023/08/06 19:15 [pubmed]
PHST- 2023/08/06 12:21 [entrez]
PHST- 2022/12/01 00:00 [pmc-release]
AID - 10.34172/aim.2022.125 [doi]
PST - epublish
SO  - Arch Iran Med. 2022 Dec 1;25(12):798-806. doi: 10.34172/aim.2022.125.